A new drug for prostate cancer, which delivers a precisely targeted dose of radiation to cancer cells, can keep cancer at bay, a phase I trial reports. The ‘search and destroy’ treatment shrank ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

United Theranostics is scaling a targeted radioactive treatment that has shown a 60% reduction in cancer progression compared ...

In prostate cancer, hormone therapy is treatment to keep the cancer cells from getting testosterone, the main male hormone (androgen). Hormone therapy for prostate cancer is also called ...

The new formulation should increase the batch size by approximately 50% and will offer the potential to expand access to patients in new geographic locations. The FDA has accepted a new drug ...

St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC programme The patients received Lutetium (177Lu) rhPSMA-10.1 Injections at both St ...

Results from a phase 3 trial led to the approval of leuprolide mesylate as a 3-month formulation for patients with advanced prostate cancer. The FDA has approved leuprolide mesylate (Camcevi) 3-month ...

The University College London (UCL) sponsored study evaluates safety, tolerability and radiation dosimetry of an investigational alpha‑emitting PSMA‑targeted radiopharmaceutical therapy, building on ...

Dear Dr. Roach: About six years ago, I was diagnosed with prostate cancer. I chose to have a high-intensity focused ultrasound (HIFU), which ultimately wasn't successful. I was told that surgery after ...

Nice to meet you. I run the "Anticancer Drug Encyclopedia." I am a practicing pharmacist and hold certifications and specialized qualifications in the field of oncology. In my daily work, I have heard ...